9EP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginTTM gross margin near 98% shows that Enanta’s revenue streams can carry substantial gross profitability when realized. This supports the economics of its partnership and royalty-oriented model, although operating expenses currently prevent that gross profit from translating into overall earnings.
Improved Leverage And Positive EquityThe sharp reduction in debt and positive equity base improve financial flexibility relative to prior periods. Lower leverage can reduce balance-sheet pressure and preserve more options for funding pipeline development, even though continued losses could erode this cushion if they persist.
RSV Pipeline Advancing Toward Late-stage TrialsAdvancing zelicapavir into a registrational Phase 2b/3 program provides a tangible path toward a potentially important future product opportunity. Late-stage development can improve strategic relevance and partnership prospects, while expected topline data establish a meaningful development milestone.
Bears Say
Persistent And Substantial Operating LossesDeeply negative profitability indicates that Enanta’s current revenue base does not cover its operating cost structure. Although losses have narrowed from earlier periods, sustained deficits can consume equity, constrain investment choices, and leave future financial performance dependent on successful pipeline execution.
Declining Revenue And Limited Top-line MomentumThe prolonged revenue decline suggests that existing commercial and collaboration economics are not currently providing reliable growth. Without renewed product, royalty, milestone, or partnership contributions, weaker top-line momentum makes it harder to absorb fixed R&D costs and move toward sustainable profitability.
Ongoing Cash Burn And External Funding DependencePersistent negative operating and free cash flow means the company is not self-funding its operations or pipeline. Even with an improved burn rate, continued reliance on balance-sheet resources or external capital can reduce strategic flexibility and increase financing pressure over the coming quarters.
Enanta Pharmaceuticals News
9EP FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is CHF319.20M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 45 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Aug 10, 2026. The company reported -CHF0.557 earnings per share for the quarter, missing the consensus estimate of -CHF0.424 by -CHF0.133.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -0.6.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 29,125,402 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -CHF0.557 in its last earnings report, missing expectations of -CHF0.424. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:9EP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enanta Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF16.59 (― Upside)
CHF16.59 (― Upside)
Blogger Sentiment
Neutral
CH:9EP Sentiment 67%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
9EP Stock 12 Month Forecast
Average Price Target
―Abeona Therapeutics
―
Tectonic Therapeutic
―
Allogene Therapeutics
―
Jade Biosciences
―
Neumora Therapeutics, Inc.
―